684 results on '"Punt, C."'
Search Results
2. FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty
3. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
4. The association between preoperative fatigue and instrumental activities in daily living with complications and length of hospital stay in patients undergoing colorectal surgery
5. Tumoren van dunne en dikke darm
6. Modulation of Hypoxia in Murine Liver Metastases of Colon Carcinoma by Nicotinamide and Carbogen
7. Interconnectivity between molecular subtypes and tumor stage in colorectal cancer
8. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
9. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
10. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial
11. Comparison of symptom clusters associated with fatigue in older and younger survivors of colorectal cancer
12. State of the Art in Dendritic Cell Vaccination
13. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study
14. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials
15. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)
16. Mitochondrial microsatellite instability in patients with metastatic colorectal cancer
17. A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion
18. The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis
19. Hepatozelluläres Karzinom
20. Gallenblasen-/Gallengangkarzinom
21. Hepatozelluläres Karzinom
22. Gallenblasen-/Gallengangkarzinom
23. Pankreaskarzinom
24. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers
25. Therapie mit Zytokinen beim fortgeschrittenen Nierenzellkarzinom
26. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case–control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy
27. Monotherapy and Combination Therapy with Interferon-α, Interferon-γ, and Tumor Necrosis Factor-α in Metastatic Renal Cell Carcinoma
28. O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer
29. RE: Effects of adjuvant chemotherapy on recurrence, survival and quality of life in stage II colon cancer patients: a 24-month follow-up
30. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study)
31. Real-world resource use and costs of adjuvant treatment for stage III colon cancer
32. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial†
33. Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach
34. Assessment of Blood Hemodynamics by USPIO-Induced R 1 Changes in MRI of Murine Colon Carcinoma
35. Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
36. Dendritic cell vaccination and immune monitoring
37. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
38. Reproducibility and biological basis of in vivo T2* magnetic resonance imaging of liver metastasis of colorectal cancer
39. In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients
40. Targeted therapy in advanced colorectal cancer, an update
41. Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
42. Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors
43. Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas
44. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer
45. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer
46. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
47. Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer
48. 272 10-YEAR FOLLOW-UP OF A RANDOMISED CONTROLLED TRIAL COMPARING NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY VERSUS SURGERY ALONE FOR OESOPHAGEAL CANCER (CROSS)
49. O-19 Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors
50. SO-30 Adjuvant systemic chemotherapy versus active surveillance following upfront resection of isolated synchronous colorectal peritoneal metastases: Propensity score-matched analysis of a nationwide registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.